|
Place de cotation: AMSTERDAM
STOCK EXCHANGE
IsoTis
has a product portfolio with several innovative and proprietary natural
and synthetic bone graft substitutes on the market and others in development,
an established North American independent distribution network and an expanding
international presence. IsoTis’ main commercial operations are based in
Irvine, California, and its international sales headquarters are based
in Lausanne, Switzerland.
http://www.isotis.com/
IsoTis
Receives Key US Patent for Accell(R) Technology
(29/11/06
08:17 CET)
November
29, 2006 – IsoTis S.A. (SWX/Euronext: ISON) (TSX: ISO), the orthobiologics
company, today announced that the U.S. Patent and Trademark Office (U.S.
PTO) has awarded US patent no 7,132,110 covering IsoTis’ groundbreaking
Accell technology.
The
Accell(R) natural human BMP (bone morphogenetic protein) technology forms
the basis of IsoTis’ Accell bone graft substitute product platform, which
has fuelled the company’s double digit revenue growth for eight consecutive
quarters. IsoTis’ current flagship products, Accell Plus(TM), Accell Putty(TM)
and Accell TBM(TM) were launched between 2002 and 2004
(originally
under the brand names Accell Connexus, Accell DBM 100, and Accell Total
Bone Matrix). The Accell products now represent two thirds of IsoTis’ US
sales, and around half of its global sales. IsoTis reported total revenues
of $ 30.8 million for the first 9 months of 2006.
Pieter
Wolters, President and CEO of IsoTis said, “We are very pleased with this
key Accell patent, which asserts our innovation leadership in the rapidly
growing orthobiology market. We believe the current Accell products already
give IsoTis a competitive advantage in the orthobiology segment of the
orthopedic market. We expect our next generation Accell products to
contain
an even higher concentration of natural human BMPs and to have even better
handling characteristics. Once we have secured regulatory clearance for
our next generation Accell products, we intend to demonstrate their clinical
efficacy in randomized prospective clinical trials that will be initiated
in the first half of 2007.”
Source : IsoTis
Provider : Euronext Amsterdam
|
